STOCKHOLM, Sweden, April 16, 2003 (PRIMEZONE) -- Meda (Other OTC:MDABF) (Stockholm:MEDAa) announces that the company has acquired the rights in the U.K. and Sweden to the well-known analgesic drug Distalgesic(R) from the American pharmaceutical company Eli Lilly and Company.
The deal sets up Meda to take over the medical registrations and the use of the trademark for a purchase value of 24 MSEK. Annual turnover is around 20 MSEK. Distalgesic(R) is an oral drug for the treatment of moderate to severe pain. "Meda continues the expansion within Pharma which is the prioritised business area. We are glad to announce that Meda is able to acquire Distalgesic(R). The product fits well with our portfolio in the pain and inflammatory area. Distalgesic(R) is one of the most recognisable analgesic brands by physicians in the UK. Our position in the UK will be strengthened through this deal," said Anders Lonner, CEO of Meda.
For further information, please contact: Meda Anders Larnholt, Investor Relations phone. +46 8 630 19 00
Meda AB (publ) is the Swedish Specialty Pharmaceutical Company. Meda markets prescription and over-the-counter drugs and medical devices. Meda is listed on the Stockholm Stock Exchange.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2003/04/16/20030416BIT00620/wkr0001.doc
http://www.waymaker.net/bitonline/2003/04/16/20030416BIT00620/wkr0002.pdf
http://www.waymaker.net/bitonline/2003/04/16/20030416BIT00620/wkr0003.doc
http://www.waymaker.net/bitonline/2003/04/16/20030416BIT00620/wkr0004.pdf